A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521
given orally for 12 weeks, in patients with symptomatic Pulmonary Arterial Hypertension
(PAH).